What is Anika Therapeutics's D&A?

Anika Therapeutics (ANIK) reported D&A of $1.41M in Q1 2026.

How has Anika Therapeutics's D&A changed year-over-year?

Anika Therapeutics's D&A increased by 1.7% year-over-year, from $1.38M to $1.41M.

What is the long-term trend for Anika Therapeutics's D&A?

Over 4 years (2021 to 2025), Anika Therapeutics's D&A has grown at a -4.6% compound annual growth rate (CAGR), from $6.48M to $5.37M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Anika Therapeutics ANIK D&A

D&A at other companies

VericelVCEL

$3.27M+21.6%

Zimmer Biomet HoldingsZBH

$270M+6.1%

Pacira BioSciences, Inc.PCRX

$21.33M+0.8%

BioventusBVS

$11.21M-5.6%

Xtant Medical HoldingsXTNT

$534K-50.3%

Globus MedicalGMED

$69.86M+6.4%

Other financials

Income statement

See full

Revenue$29.6M+13.2%

Net income-$5.1M-3.8%

Balance sheet

See full

Cash & equivalents$41.0M-23.1%

Total debt$25.7M+1.2%

Total equity$133.9M-9.8%

Total assets$179.4M-5.9%

Cash flow

See full

Operating cash flow-$4.8M-3,628%

CapEx$1.4M-49.3%

Free cash flow-$6.3M-112%

Valuation

See full

Market cap$204.37M+31.6%

Enterprise value$189.09M+48.7%

P/S1.8×+0.1×

Profitability

See full

Net margin-9.8%-4.4pp

FCF margin0.9%—

Returns & leverage

See full

Return on equity-8%-3.4pp

Debt / equity0.2×0.0×

Current ratio4.5×-1.3×

Where this comes from

Reported directly by Anika Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.

The official record: Anika Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Anika Therapeutics's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Anika Therapeutics's D&A?: Anika Therapeutics (ANIK) reported D&A of $1.41M in Q1 2026.
How has Anika Therapeutics's D&A changed year-over-year?: Anika Therapeutics's D&A increased by 1.7% year-over-year, from $1.38M to $1.41M.
What is the long-term trend for Anika Therapeutics's D&A?: Over 4 years (2021 to 2025), Anika Therapeutics's D&A has grown at a -4.6% compound annual growth rate (CAGR), from $6.48M to $5.37M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.